Common adverse events following immunization with moderna Covid-19 vaccine among Vietnamese adults at Hanoi Medical University in 2021

Abstract

The rapid creation of vaccinations has increased the risk of vaccine safety. In less than two years, a significant number of COVID-19 vaccines were developed and approved in various countries to control the COVID-19 pandemic. This study was conducted to identify the common adverse events following immunization with mRNA-1273 (Moderna COVID-19) vaccine among adults in 2021. A cross-sectional study using randomized sampling was conducted in Hanoi, Vietnam, with 766 participants. The results show that the prevalence of AEFIs after the 1st dose was significantly lower than after the 2nd dose (41.25% vs. 85.64%, p < 0.05). Local effects, fever, fatigue, and increased pain sensation were the most common side effects encountered in both 1st and 2nd dose. The AEFIs are mostly mild and automatically wore off after one to three days. Therefore, the Moderna COVID-19 vaccine is safe for injection.

Common Adverse Events from Mixing COVID-19 Vaccine Booster in Hanoi, Vietnam

“…To the best of our knowledge, the present study is the first study in Vietnam that provides safety data on various combined vaccination strategies for COVID-19 prevention. While previous studies in Vietnam considered the safety of two matching doses of Pfizer [ 12 ], Moderna [ 13 ] vaccines, or a single dose [ 16 ], this study delves deeper into the safety implications of combining different types of vaccines for the second booster dose. The study confirmed previous evidence on the safety of mixed COVID-19 vaccines [ 10 ].…”

“…Previous evidence in Vietnam suggested that the matching of the same COVID-19 vaccine for a booster is safe with the PfizerBioNTech [ 12 ] or mRNA-1273 (Moderna) [ 13 ]. Less is known about the safety of mixed doses between different vaccines in two doses of vaccination [ 14 ].…”

“…Previous evidence in Vietnam suggested that the matching of the same COVID-19 vaccine for a booster is safe with the PfizerBioNTech [12] or mRNA-1273 (Moderna) [13].…”